- Home
- NPFD vs EBS Comparison
NPFD vs EBS Comparison
Compare NPFD & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- EBS
- Stock Information
- Founded
- NPFD 2021
- EBS 1998
- Country
- NPFD United States
- EBS United States
- Employees
- NPFD N/A
- EBS N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- EBS Health Care
- Exchange
- NPFD Nasdaq
- EBS Nasdaq
- Market Cap
- NPFD 462.7M
- EBS 353.9M
- IPO Year
- NPFD N/A
- EBS 2006
- Fundamental
- Price
- NPFD $19.35
- EBS $6.99
- Analyst Decision
- NPFD
- EBS Strong Buy
- Analyst Count
- NPFD 0
- EBS 3
- Target Price
- NPFD N/A
- EBS $14.33
- AVG Volume (30 Days)
- NPFD 64.7K
- EBS 1.4M
- Earning Date
- NPFD 01-01-0001
- EBS 08-05-2025
- Dividend Yield
- NPFD 6.28%
- EBS N/A
- EPS Growth
- NPFD N/A
- EBS N/A
- EPS
- NPFD N/A
- EBS N/A
- Revenue
- NPFD N/A
- EBS $965,400,000.00
- Revenue This Year
- NPFD N/A
- EBS N/A
- Revenue Next Year
- NPFD N/A
- EBS $18.88
- P/E Ratio
- NPFD N/A
- EBS N/A
- Revenue Growth
- NPFD N/A
- EBS N/A
- 52 Week Low
- NPFD $14.50
- EBS $4.02
- 52 Week High
- NPFD $18.07
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- NPFD 67.62
- EBS 59.80
- Support Level
- NPFD $19.17
- EBS $6.21
- Resistance Level
- NPFD $19.36
- EBS $6.95
- Average True Range (ATR)
- NPFD 0.19
- EBS 0.39
- MACD
- NPFD 0.03
- EBS 0.03
- Stochastic Oscillator
- NPFD 93.58
- EBS 76.00
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.